Table I.
Association between miR-505 expression and the clinicopathological features of patients with breast cancer.
| miR-505 expression | ||||
|---|---|---|---|---|
| Feature | Total no. (n=128) | Low (n=66) | High (n=62) | P-value |
| Age, years | 0.798 | |||
| ≤50 | 44 | 22 | 22 | |
| >50 | 84 | 44 | 40 | |
| Tumor size, cm | 0.160 | |||
| ≤2 | 62 | 28 | 34 | |
| >2 | 66 | 38 | 28 | |
| ER status | 0.927 | |||
| Negative | 80 | 41 | 39 | |
| Positive | 48 | 25 | 23 | |
| PR status | 0.412 | |||
| Negative | 81 | 44 | 37 | |
| Positive | 47 | 22 | 25 | |
| HER2 status | 0.665 | |||
| Negative | 87 | 46 | 41 | |
| Positive | 41 | 20 | 21 | |
| Distant metastasis | 0.013 | |||
| Negative | 90 | 40 | 50 | |
| Positive | 38 | 26 | 12 | |
| TNM stage | 0.002 | |||
| I–II | 60 | 22 | 38 | |
| III–IV | 68 | 44 | 24 | |
ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; miR-505, microRNA-505; TNM, Tumor-Node-Metastasis.